Gemi Pharmacure (PTY) Ltd, a 100% Botswana citizen-owned company, is developing the first and only fully integrated, state-of-the-art multiple complex facilities for the full manufacturing (from Active Pharmaceutical Ingredients (API)) of generic pharmaceuticals including anti-retrovirals (ARVs), anti-tuberculosis, anti-malarials, analgesics (painkillers), anti-hypertensives, anti-diabetes, and other drugs, especially those used in the treatment of HIV/AIDS and related opportunistic infections. The project is being developed with the technical assistance of the United Nations Industrial Development Organization (UNIDO), with all the technology and expertise provided by innovative and vertically integrated pharmaceutical companies.
NNE Pharmaplan (Novo Nordisk Engineering), the worlds leading pharmaceutical engineering and consulting company , has been commissioned to design the facilities to comply with the most stringent international standards including US FDA, WHO Geneva, PIC/S and MCC South Africa. The Conceptual Design has been completed, and a comprehensive Project Report compiled; at full operation, the facilities will employ about 1500 people with bias towards new graduate scientists and other previously unemployed youth and women, where possible.
GEMI seeks to capture the majority of the Botswana ARV Market currently standing at about US$50 million per annum, before expanding distribution to cover Southern African Development Community (SADC), a region of about 250 million people. In time, we will pursue contracts/licensing by international pharmaceutical companies to produce their branded generics and patented pharmaceuticals.